APIs para pesquisa e impurezas

Roxithromycin impurity I is a natural metabolite of roxithromycin. The substance has been synthesized in order to serve as an analytical impurity standard for HPLC. Roxithromycin impurity 1 is also a metabolite of roxithromycin, which has been shown to produce pharmacological effects similar to those seen with the parent compound. Roxithromycin impurity I is not an API, but has been developed as a HPLC analytical impurity standard and will be used for metabolism studies.

4-(Phthalazin-1-yloxy)aniline is an analog of cyclin-dependent kinase (CDK) inhibitors that has shown promising anticancer activity. It inhibits the activity of CDKs, which are enzymes involved in regulating cell division and proliferation. This compound has been tested on Chinese hamster ovary cells and has demonstrated potent antiproliferative activity against various cancer cell lines. 4-(Phthalazin-1-yloxy)aniline induces apoptosis in tumor cells, leading to their death. This compound may be a potential candidate for the development of novel anticancer drugs that target CDKs and promote tumor cell death. Additionally, this compound can be detected in urine samples, making it a useful biomarker for cancer diagnosis and monitoring.

(S)-3-((R)-5-Oxopyrrolidine-2-carbonyl)thiazolidine-4-carboxylic acid is a drug product of the drug development industry. It is a metabolite of 3-(1,2,4-triazol-1-ylmethyl)thiazolidine-4-carboxylic acid and has been used as an analytical standard for HPLC methods. The compound has been shown to be naturally occurring in humans. (S)-3-(1,2,4-Triazol-1ylmethyl)thiazolidine 4 carboxylic acid is also used as the impurity standard for the API 3-(1,2,4 triazol 1ylmethyl)thiazolidine 4 carboxylic acid.

Methyl mycophenolate impurity E is a reactive, propargylamine-containing, monosodium salt with immunosuppressive properties. It is used in the treatment of cancer by inhibiting the production of white blood cells, which are needed to fight infection. Methyl mycophenolate impurity E has shown antitumor activity and can be used for the treatment of some types of cancer. It is metabolized in vivo to methyl mycophenolate and inhibits protein synthesis by alkylating DNA.

Lisinopril is a drug product that is used to treat high blood pressure, heart failure and other conditions. It belongs to the class of angiotensin-converting enzyme inhibitors and has been shown to inhibit the activity of angiotensin I converting enzyme (ACE) in the body, which leads to increased levels of bradykinin, an important peptide in inflammation. Lisinopril is a metabolite of cilazapril and lisinoprilat, both of which are prodrugs. Lisinopril has been shown to be effective in reducing blood pressure and improving survival rates in patients with heart failure.

Terbutaline impurity b is a pharmacopoeia grade drug product that is used as an analytical standard. It is also used in the synthesis of terbutaline, which is a drug that has been approved by the FDA to treat bronchospasm, asthma and other lung disorders. Terbutaline impurity b may be found in natural sources or may be synthesized. This impurity can be custom synthesized using HPLC-grade reagents and can be obtained at high purity levels.

(3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-[methyl[(2-hydroxy-2-methylpropyl)sulfonyl]amino]-5-pyrimidinyl]-3,5-dihydroxy- 6-heptenoic acid sodium salt is a synthetic drug product. It is an impurity standard in the synthesis of Metabolism studies. The CAS number is 1714147-50-8 and the chemical name is (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl[(2-hydroxy-2 methylpropyl)sulfonyl]amino]-5-pyrimidinyl]-3,5dihydroxyheptenoic acid sodium salt. The molecular weight is 781

Duloxetine is a drug product that belongs to the class of drugs known as selective serotonin and norepinephrine reuptake inhibitors. Duloxetine is a metabolite of duloxetine phenyl carbamate, which is an impurity standard for HPLC analysis. Duloxetine has been shown to inhibit the metabolism of serotonin and norepinephrine in the brain, leading to increased amounts of these neurotransmitters. This medication has been studied in niche populations such as those with depression and diabetic neuropathy. Duloxetine also has high purity standards, meeting the requirements of pharmacopoeia.

Dispersants are substances that are used to break up and disperse particles in a liquid. The dispersant 11-[3-(dimethylamino)propyl]-6,11-dihydrodibenz[b,e]oxepin-11-ol is an active substance that is used in the production of granules, tablets or other solidified forms of medicaments. It is a substance that has a physiologically active effect on humans and animals. This product can be applied as droplets or particles.

Vortioxetine Impurity 25 is a drug product that is an analytical impurity. It is a natural impurity found in the synthetic process of Vortioxetine, which is an active pharmaceutical ingredient (API). It has been shown to have pharmacological effects in humans and animals. This compound has been synthesized for use as a standard for HPLC assays. The CAS number for this substance is 1639263-80-1.

Desfluoro impurity is a drug product that is an analytical standard for the identification of impurities in API. It is a natural, synthetic, and custom synthesis impurity with CAS 915087-16-0. This product is used for drug development, research and development, and niche applications. Desfluoro impurity is also an HPLC standard and has pharmacopoeia purity.

Impurity A is an impurity of the drug product, dexamethasone. The impurity is a natural metabolite of dexamethasone that is found in the urine of patients taking this medication. Impurity A is chemically identified using HPLC and its purity verified using GC-MS and LC-MS. This impurity can be used as a reference standard for analytical purposes and as an impurity standard for pharmacopoeia testing.

Please enquire for more information about Acrolein-d4 including the price, delivery time and more detailed product information at the technical inquiry form on this page

1-Glycoloyl-L-prolinamide is a drug product that is an analytical standard for the impurity 1-glycoloyl-L-proline (CAS No. 96166-39-1) in the API 1,4,5,6-tetrahydrobenzothiazole (CAS No. 86687-93-0). It has been synthesized to be used as an impurity standard and is provided at a purity of 98.0% or greater by weight. This chemical compound can be used in research and development for the production of drugs as well as in pharmaceutical manufacturing.

Rosuvastatin anhydro lactone is a pure chemical compound that is used as an analytical reference standard for high-performance liquid chromatography (HPLC) for the determination of purity and identification of impurities in pharmaceuticals. It is also utilized as a drug development, API impurity, and HPLC standard. Rosuvastatin anhydro lactone is a metabolite of rosuvastatin and is chemically designated as C22H29NO3. The CAS number for rosuvastatin anhydro lactone is 1246665-85-9.

2-[[4-(2-Pyridylsulfamoyl)phenyl]azo]hydroxybenzene is an impurity found in sulfasalazine. It is a metabolite that is formed by the P450 system in the liver. The metabolic process of 2-[[4-(2-Pyridylsulfamoyl)phenyl]azo]hydroxybenzene has been studied in detail and has been shown to be a major contributor to the pharmacokinetic profile of sulfasalazine. This substance also exhibits antimicrobial activity and inhibits the growth of bacteria, fungi, and viruses.

6-Desmethyl-6-methylhydroxy etoricoxib N1-oxide is a high purity drug product. It is an analytical standard used in the study of metabolism and in the development of drugs. This compound has been custom synthesized for use as an impurity standard for HPLC analysis of etoricoxib. 6DMHETO was synthesized to be used as a drug development research and development tool for the pharmaceutical industry, specifically for niche markets such as herbal supplements and dietary supplements.

L-745,870 is a subchronic atypical antipsychotic agent that is a potent D4 receptor agonist. Its efficacy in treating various mental disorders has been demonstrated in clinical studies with animals. L-745,870 has shown antidyskinetic activity in animal models of Parkinson's disease and dyskinesia. The molecular target for this drug is the dopamine D4 receptor. Clinical development of L-745,870 has begun in human studies.